The biopharma company, formerly US Genomics, has closed an $11.5m series B round with investment from Ascension Health and Cain Brothers among others.

The Novartis-backed molecular drug company has earned $4m in milestone payments from Infinity Pharmaceuticals to add to $41m in equity funding raised since 2007.

Biogen Idec has invested $45m in pharmaceuticals company Portola as part of a commercialisation agreement that could eventually be worth more than $500m.

Biopharma company Population Genetics has raised series B funding from backers including agribusiness firm Syngenta.

The hospital IT management firm, backed by corporate venturing unit Ascension Health Ventures has secured new investment from existing VC backers.

Siemens-backed medical device company Sphere Medical is set for an initial public offering, from which it expects to raise $24m.

The Biopharma company will collaborate with existing investor Ipsen to develop new botulinum treatments in a deal that could be worth more than $90m to Syntaxin.

Amgen-backed biopharma company Miragen has signed a research agreement with Les Labaratoires Servier that the firms state could reach $1bn, with $45m being invested in Miragen upfront.